NCT00235937已完成2 期
An Open, Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex® 1mg Per os/Day and Zoladex® 3.6 mg Sub Cut/Monthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 45
- 试验地点
- 7
- 主要终点
- Determine the feasibility and efficacy of the combination of these 2 drugs in these patients
研究概览
简要总结
The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and Zoladex® 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent, premenopausal women 18 years or older, histologically or cytologically confirmed locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available,, one or more measurable lesions, life expectancy more than 6 months, normal biological parameters.
排除标准
- •Presence of life-threatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe or uncontrolled systemic disease, pituitary adenoma, High risk of medullar compression.
结局指标
主要结局
Determine the feasibility and efficacy of the combination of these 2 drugs in these patients
次要结局
- To assess clinical benefit rate, time to progression, duartion of response and safety in patients treated with the combination of these 2 drugs
研究者
研究点 (7)
Loading locations...
相似试验
撤回
2 期
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerCancer of the Bile DuctGallbladder CancerNCT00386516Galectin Therapeutics Inc.
进行中（未招募）
2 期
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionHIV-1 InfectionNCT05729568Gilead Sciences83
已完成
2 期
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutGoutHyperuricemiaNCT02252835CymaBay Therapeutics, Inc.32
已完成
1 期
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNCT03214250Parker Institute for Cancer Immunotherapy129
已完成
2 期
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursNeuroendocrine TumorsPancreatic NeoplasmsNCT02402062Grupo Espanol de Tumores Neuroendocrinos17